OxyContin maker Purdue will no longer market opioid drugs to doctors

OxyContin maker Purdue will no longer market opioid drugs to doctors

OxyContin maker Purdue will no longer market opioid drugs to doctors

In a surprise move, Purdue Pharma, the manufacturer of the opiate painkiller OxyContin, has said that it will reduce its direct sales force and stop the direct marketing of opiates to doctors.

"We would have more success in encouraging cautious prescribing if drug companies stopped promoting aggressive prescribing", he told the Times.

"Effective Monday, February 12, 2018, our field sales organization will no longer be visiting your offices to engage you in discussions about our opioid products", Kwarcinski wrote in a letter to prescribers.

Purdue and other opioid drugmakers and pharmaceutical distributors continue defending themselves against hundreds of local and state lawsuits seeking to hold the industry accountable for the drug overdose epidemic. Doctors with questions about opioids will be directed to the company's medical affairs department. Symproic is used to treat opioid-related constipation. The drug was marketed as a non-addictive treatment for chronic pain. Purdue, which has reportedly generated approximately $35 billion dollars in revenue, in a statement said it had "restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers".

At least 14 states have sued Purdue, and many cities including Greenfield and Springfield in Western Massachusetts.

Yoel Romero misses weight ahead of UFC 221 fight with Luke Rockhold
The fight tonight would have marked Romero's second attempt in a row at a UFC Interim Middleweight title. However, despite the two hour allotment to get his weight down, Romero was unable to hit the mark.

The government claims the results have been tragic - and left government agencies with millions in social and health care costs.

Purdue "vigorously denies" any misconduct, saying it has consistently followed the CDC's opioid guidelines including not recommending opioids as a first option. "How could we not help fight the prescription and illicit opioid abuse crisis?"

Up to one in four people who received prescriptions for opioid drugs such as OxyContin struggle with opioid addiction, the Centers for Disease Control and Prevention says.

Purdue's promotions exaggerated the drug's safety and risks of addiction, leading to lawsuits and federal investigations.

Related news